1. Home
  2. BDSX vs BDTX Comparison

BDSX vs BDTX Comparison

Compare BDSX & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$24.00

Market Cap

153.3M

Sector

Health Care

ML Signal

HOLD

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

HOLD

Current Price

$2.04

Market Cap

171.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BDSX
BDTX
Founded
2005
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Precision Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
153.3M
171.9M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
BDSX
BDTX
Price
$24.00
$2.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
7
Target Price
$32.50
$9.67
AVG Volume (30 Days)
66.3K
642.5K
Earning Date
05-04-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
130.71
EPS
N/A
N/A
Revenue
$88,499,000.00
N/A
Revenue This Year
$25.26
N/A
Revenue Next Year
$19.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
24.08
N/A
52 Week Low
$0.35
$1.60
52 Week High
$25.52
$4.94

Technical Indicators

Market Signals
Indicator
BDSX
BDTX
Relative Strength Index (RSI) 60.37 59.22
Support Level $19.26 $1.96
Resistance Level $24.47 $2.26
Average True Range (ATR) 1.73 0.10
MACD 0.09 0.04
Stochastic Oscillator 70.61 77.88

Price Performance

Historical Comparison
BDSX
BDTX

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Share on Social Networks: